Guerbet S. A. (GBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guerbet S. A. (GBT) has a cash flow conversion efficiency ratio of 0.034x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€12.48 Million ≈ $14.59 Million USD) by net assets (€372.13 Million ≈ $435.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guerbet S. A. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Guerbet S. A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Guerbet S. A. carry for a breakdown of total debt and financial obligations.
Guerbet S. A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guerbet S. A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
0.019x |
|
Silicon Power Computer & Communications
TWO:4973
|
0.027x |
|
Ekovest Bhd
KLSE:8877
|
0.028x |
|
Bluerock Acquisition Corp. Class A Ordinary Shares
NASDAQ:BLRK
|
10.328x |
|
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
|
0.041x |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
0.148x |
|
United Security Bancshares
NASDAQ:UBFO
|
0.050x |
|
DNF Co.Ltd
KQ:092070
|
0.029x |
Annual Cash Flow Conversion Efficiency for Guerbet S. A. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Guerbet S. A. from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Guerbet S. A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €391.57 Million ≈ $457.79 Million |
€81.22 Million ≈ $94.95 Million |
0.207x | +185.97% |
| 2023-12-31 | €378.27 Million ≈ $442.24 Million |
€27.44 Million ≈ $32.08 Million |
0.073x | -9.56% |
| 2022-12-31 | €379.57 Million ≈ $443.76 Million |
€30.44 Million ≈ $35.59 Million |
0.080x | -71.99% |
| 2021-12-31 | €405.09 Million ≈ $473.60 Million |
€115.97 Million ≈ $135.58 Million |
0.286x | -12.58% |
| 2020-12-31 | €367.75 Million ≈ $429.94 Million |
€120.43 Million ≈ $140.80 Million |
0.327x | -2.91% |
| 2019-12-31 | €389.19 Million ≈ $455.01 Million |
€131.27 Million ≈ $153.47 Million |
0.337x | +60.82% |
| 2018-12-31 | €366.76 Million ≈ $428.78 Million |
€76.92 Million ≈ $89.93 Million |
0.210x | +28.02% |
| 2017-12-31 | €342.14 Million ≈ $400.00 Million |
€56.05 Million ≈ $65.53 Million |
0.164x | +33.31% |
| 2016-12-31 | €314.80 Million ≈ $368.03 Million |
€38.69 Million ≈ $45.23 Million |
0.123x | -47.13% |
| 2015-12-31 | €282.44 Million ≈ $330.20 Million |
€65.65 Million ≈ $76.75 Million |
0.232x | +0.42% |
| 2014-12-31 | €259.10 Million ≈ $302.92 Million |
€59.98 Million ≈ $70.12 Million |
0.231x | -6.97% |
| 2013-12-31 | €238.26 Million ≈ $278.55 Million |
€59.28 Million ≈ $69.30 Million |
0.249x | +26.10% |
| 2012-12-31 | €226.21 Million ≈ $264.46 Million |
€44.63 Million ≈ $52.18 Million |
0.197x | +2.26% |
| 2011-12-31 | €214.80 Million ≈ $251.12 Million |
€41.44 Million ≈ $48.45 Million |
0.193x | +9.66% |
| 2010-12-31 | €210.52 Million ≈ $246.12 Million |
€37.04 Million ≈ $43.30 Million |
0.176x | -2.95% |
| 2009-12-31 | €205.31 Million ≈ $240.02 Million |
€37.22 Million ≈ $43.51 Million |
0.181x | +6.39% |
| 2008-12-31 | €185.73 Million ≈ $217.13 Million |
€31.65 Million ≈ $37.00 Million |
0.170x | -27.70% |
| 2007-12-31 | €170.96 Million ≈ $199.86 Million |
€40.29 Million ≈ $47.11 Million |
0.236x | +244.21% |
| 2006-12-31 | €152.14 Million ≈ $177.86 Million |
€10.42 Million ≈ $12.18 Million |
0.068x | -76.90% |
| 2005-12-31 | €141.16 Million ≈ $165.03 Million |
€41.84 Million ≈ $48.92 Million |
0.296x | +10.90% |
| 2004-12-31 | €120.21 Million ≈ $140.54 Million |
€32.13 Million ≈ $37.56 Million |
0.267x | -- |
About Guerbet S. A.
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solut… Read more